T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts

BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy has established itself as a potent therapeutic option for certain patients with relapsed/refractory (R/R) hematologic malignancies. To date, four CD19-redirected CAR-T cell products have been granted the United States Food and Drug Administr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasiri, Fatemeh, Safarzadeh Kozani, Pooria, Rahbarizadeh, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978144/
https://www.ncbi.nlm.nih.gov/pubmed/36875091
http://dx.doi.org/10.3389/fimmu.2023.1063838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978144/
https://www.ncbi.nlm.nih.gov/pubmed/36875091
http://dx.doi.org/10.3389/fimmu.2023.1063838

Ejemplares similares